标题
Fenofibrate
作者
关键词
-
出版物
DRUGS
Volume 71, Issue 14, Pages 1917-1946
出版商
Springer Nature
发表日期
2011-10-05
DOI
10.2165/11208090-000000000-00000
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances
- (2014) Robert Krysiak et al. Pharmacological Reports
- Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome
- (2013) Jean-Claude Ansquer et al. American Journal of Cardiovascular Drugs
- Effect of Simvastatin and Fenofibrate on Cytokine Release and Systemic Inflammation in Type 2 Diabetes Mellitus With Mixed Dyslipidemia
- (2011) Robert Krysiak et al. AMERICAN JOURNAL OF CARDIOLOGY
- Fenofibrate
- (2011) Gillian M. Keating American Journal of Cardiovascular Drugs
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Fixed-Dose Combination Fenofibrate/Pravastatin 160/40 mg Versus Simvastatin 20 mg Monotherapy in Adults With Type 2 Diabetes and Mixed Hyperlipidemia Uncontrolled With Simvastatin 20 mg: A Double-Blind, Randomized Comparative Study
- (2011) Michel Farnier et al. CLINICAL THERAPEUTICS
- Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation
- (2011) M. Villarroel et al. DIABETOLOGIA
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
- (2011) et al. EUROPEAN HEART JOURNAL
- Pharmacoepidemiology Safety Study of Fibrate and Statin Concomitant Therapy
- (2010) Cheryl Enger et al. AMERICAN JOURNAL OF CARDIOLOGY
- Efficacy and Safety of Adding Fenofibrate 160 mg in High-Risk Patients With Mixed Hyperlipidemia Not Controlled by Pravastatin 40 mg monotherapy
- (2010) Michel Farnier et al. AMERICAN JOURNAL OF CARDIOLOGY
- Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg
- (2010) Jin Wi et al. ATHEROSCLEROSIS
- Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia
- (2010) Kwang Kon Koh et al. ATHEROSCLEROSIS
- Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
- (2010) Andrew M. Tonkin et al. CIRCULATION
- Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients
- (2010) Sandra J. Hamilton et al. CLINICAL SCIENCE
- Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study
- (2010) Michael H. Davidson et al. CLINICAL THERAPEUTICS
- Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R3i)
- (2010) J.C. Fruchart et al. CURRENT MEDICAL RESEARCH AND OPINION
- Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
- (2010) Marshall Elam et al. CURRENT OPINION IN LIPIDOLOGY
- Pleiotropic Effects of Atorvastatin and Fenofibrate in Metabolic Syndrome and Different Types of Pre-Diabetes
- (2010) R. Krysiak et al. DIABETES CARE
- Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2010) P. L. Drury et al. DIABETOLOGIA
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of Gemfibrozil and Fenofibrate on the Pharmacokinetics of Atorvastatin
- (2010) Lloyd R. Whitfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate–activated protein kinase activation
- (2010) Atsuko Tomizawa et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials
- (2010) John Simes et al. PLoS One
- Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease
- (2009) Jean-Charles Fruchart ATHEROSCLEROSIS
- Effects of atorvastatin 10 mg and fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: A 12-week, multicenter, randomized, open-label, parallel-group study
- (2009) Jean-Claude Ansquer et al. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
- Regulatory Effects of Fenofibrate and Atorvastatin on Lipoprotein A-I and Lipoprotein A-I:A-II Kinetics in the Metabolic Syndrome
- (2009) D. C. Chan et al. DIABETES CARE
- Advances in the Medical Treatment of Diabetic Retinopathy
- (2009) R. Simo et al. DIABETES CARE
- Preventing diabetic complications: A primary care perspective
- (2009) Paul Zimmet DIABETES RESEARCH AND CLINICAL PRACTICE
- Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2009) D. C. Burgess et al. EUROPEAN HEART JOURNAL
- Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective
- (2009) P. P. Toth INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
- (2009) Kushwin Rajamani et al. LANCET
- Fenofibrate reduces lipoprotein associated phospholipase A 2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
- (2008) Robert S. Rosenson AMERICAN HEART JOURNAL
- Expert Perspective: Reducing Cardiovascular Risk in Metabolic Syndrome and Type 2 Diabetes Mellitus Beyond Low-Density Lipoprotein Cholesterol Lowering
- (2008) Peter H. Jones AMERICAN JOURNAL OF CARDIOLOGY
- Atorvastatin and Fenofibrate Have Comparable Effects on VLDL-Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome
- (2008) Dick C. Chan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- (2008) R. Scott et al. DIABETES CARE
- Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
- (2008) T. M. E. Davis et al. DIABETOLOGIA
- Lipoprotein Management in Patients With Cardiometabolic Risk
- (2008) John D. Brunzell et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PPARα activators upregulate eNOS activity and inhibit cytokine-induced NF-κB activation through AMP-activated protein kinase activation
- (2008) Toshie Okayasu et al. LIFE SCIENCES
- Effect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients
- (2008) Robert S. Rosenson Obesity
- Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels
- (2007) Wimon Phuntuwate et al. ATHEROSCLEROSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search